Summary
• Aspire Biopharma Holdings, Inc. (ASBP) rises 13.9% in pre-market trading to $0.1082 following Nasdaq extension approval.
• Nasdaq granted ASBP an extension to maintain its listing, with compliance deadlines set for January 30 and February 17, 2026.
• The stock has shown volatility, up 3.8% weekly but down nearly 76.9% for the quarter, with a Relative Strength Index indicating potential for a rebound.
Aspire Biopharma Holdings, Inc. (ASBP) is experiencing significant pre-market gains, surging 13.9% to a current price of $0.1082, compared to its last close of $0.0950. This movement follows a recent announcement that the company received an extension from a Nasdaq hearing panel to continue listing its common stock.
Nasdaq Compliance Extension Fuels Gains
On December 12, 2025, Aspire Biopharma announced that the Nasdaq Listing Qualifications Panel has granted its request to maintain its listing on the Nasdaq Stock Market. The approval comes with conditions: the company must demonstrate compliance with Nasdaq’s Bid Price Rule by January 30, 2026, and with the Equity Rule by February 17, 2026. In line with this, Aspire will transfer its stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective as of today’s opening.
The company is focused on fulfilling these requirements after its recent financial struggles and undergoing significant changes within its operational structure. The approval continues to build momentum for Aspire as it persists in its pursuit of compliance and operational improvements.
Trading Dynamics and Market Performance
In terms of broader market dynamics, ASBP’s stock has displayed considerable volatility, with a 3.8% weekly performance increase, albeit still down nearly 76.9% for the quarter. Trading volume has seen fluctuations, with recent average volumes at 16.3 million over 10 days, compared to 35.5 million over three months.
Additionally, key technical indicators include a Relative Strength Index (RSI) standing at 34.02, which suggests potential time for a rebound; however, continued monitoring is essential amid these transitioning market conditions.
Background Considerations
Prior to the compliance extension, Aspire Biopharma provided various updates about its operational strategies. On December 4, 2025, the company shared a quarterly business update, highlighting organizational growth and advancements in their scientific team. Moreover, on December 2, 2025, Aspire submitted a Pre-IND meeting request to the U.S. FDA for its sublingual aspirin product targeting acute myocardial infarction treatment, another significant step on the path to gaining FDA approval.
Conclusion: Moving Forward Amid Transitional Challenges
With the latest approval now reflected in trading, investors will be monitoring how Aspire Biopharma’s stock continues to adapt to its operational challenges and compliance requirements in the coming sessions.